Cannabics Pharmaceutical collaborates with CTC European lab

Cannabics Pharmaceutical has began a scientific collaboration with European lab working on circulating tumor cells (CTC) count and drug sensitivity tests for cancer patients.

The blood test results enables practitioners and patients to monitor the number of circulating tumor cells as an indication for cancer characteristics, treatment efficacy and and re-occurrence. Cannabics is planning to provide patients with information regarding the effectiveness of both cannabinoid compounds and other therapies.

Cannabics Co-founder and CTO, Dr. Eyal Ballan said that many cancer patients are treated with cannabis, either in conjunction with chemotherapy or without. Their aim is to provide them with a lab test to help monitor the effectiveness of the treatment, using a simple blood test.